This inventor holds 2 USPTO granted patents. Top assignee: Bayer Aktiengesellschaft. Active years: 1998-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Monheim, DE (1998)
- Rheinfelden, DE (2002)
Company Filing History:
Years Active: 1998-2002
Title: Matthias Kuhn: Innovator in Pharmaceutical Formulations
Introduction
Matthias Kuhn is a notable inventor based in Rheinfelden, Germany. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of orally administrable preparations. With a total of 2 patents to his name, Kuhn's work has the potential to impact the medical industry positively.
Latest Patents
Kuhn's latest patents include innovative formulations that enhance the delivery of active compounds. One of his notable inventions is a semi-solid aqueous preparation for oral applications of toltrazuril sulfone. This invention comprises an active compound concentration of 0.1-20% by weight, with a specific particle size and the inclusion of polyacrylic acids and water. Another significant patent involves the preparation of orally administrable formulations of quinolone- or naphthyridonecarboxylic acids. This formulation is created by mixing these acids with embonic acid, utilizing various excipients to enhance the effectiveness of the delivery method.
Career Highlights
Kuhn is associated with Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. His work at Bayer has allowed him to focus on innovative solutions that address complex medical challenges. His contributions have been instrumental in advancing the company's research and development efforts.
Collaborations
Throughout his career, Kuhn has collaborated with esteemed colleagues, including Oliver Vetter and Reinhold Lohr. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their innovations.
Conclusion
Matthias Kuhn's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents reflect a commitment to improving oral drug delivery systems, which can lead to better patient outcomes. As he continues to develop new formulations, his contributions will undoubtedly play a crucial role in advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile